1-12 of 12
Justin L. Ricker
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The BCL-2 Inhibitor ABT-199 (GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma

Sven de Vos, MD PhD, Christopher R. Flowers, MD, Ding Wang, MD PhD, Lode J. Swinnen, Nathan Fowler, MD, Erin Reid, MD, Maryella Gifford, BS, Diane D'Amico, Martin Dunbar, DRPH, Ming Zhu, PhD, Jianning Yang, PhD, Sari H. Enschede, MD, Justin L. Ricker, MD PhD, David Chien, MD, Rod A. Humerickhouse, MD PhD, Mark Kozloff, MD
Journal: Blood
Blood (2014) 124 (21): 1722.
https://doi.org/10.1182/blood.V124.21.1722.1722
Published: 2014
Journal Articles

A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous Leukemia (AML)

Marina Konopleva, MD PhD, Daniel A. Pollyea, MD MS, Jalaja Potluri, MD, Brenda J. Chyla, PhD, Todd Busman, MS, Evelyn McKeegan, PhD, Ahmed Salem, PhD, Ming Zhu, PhD, Justin L. Ricker, MD PhD, William Blum, MD, Courtney D. DiNardo, MD, Martin Dunbar, DRPH, Rachel Kirby, Nancy Falotico, Joel D. Leverson, PhD, Rod A. Humerickhouse, MD PhD, Mack Mabry, MD, Richard M. Stone, MD, Hagop M. Kantarjian, MD, Anthony G. Letai, MD PhD
Journal: Blood
Blood (2014) 124 (21): 118.
https://doi.org/10.1182/blood.V124.21.118.118
Published: 2014
Journal Articles

CDK9 Inhibition Reverses Resistance to ABT-199 (GDC-0199) By Down-Regulating MCL-1

Jun Chen, MDPhD, Sha Jin, MS, Paul Tapang, Stephen K Tahir, PhD, Morey Smith, John Xue, Haichao Zhang, PhD, Wenqing Gao, PhD, Yunsong Tong, PhD, Richard Clark, Justin L. Ricker, MD PhD, Thomas D Penning, PhD, Daniel H Albert, PhD, Darren C Phillips, PhD, Andrew J Souers, PhD, Joel D. Leverson, PhD
Journal: Blood
Blood (2014) 124 (21): 2161.
https://doi.org/10.1182/blood.V124.21.2161.2161
Published: 2014
Journal Articles

Phase 1 Study of ABT-348, A Dual Aurora/VEGF-Receptor Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies.

Guillermo Garcia-Manero, MD, Raoul Tibes, MD, Yi-Lin Chiu, PhD, Hao Xiong, PhD, Qin Qin, Peter Ansell, PhD, Daniel H. Albert, PhD, BSc, Chris Tse, PhD, Brian Oliver, Karim Sajwani, MS, Mark D. McKee, MD, Justin L. Ricker, MD, PhD, H. Jean Khoury, MD
Journal: Blood
Blood (2012) 120 (21): 2617.
https://doi.org/10.1182/blood.V120.21.2617.2617
Published: 2012
Journal Articles

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

Clinical Trials & Observations
Guillermo Garcia-Manero, Hui Yang, Carlos Bueso-Ramos, Alessandra Ferrajoli, Jorge Cortes, William G. Wierda, Stefan Faderl, Charles Koller, Gail Morris, Gary Rosner, Andrey Loboda, Valeria R. Fantin, Sophia S. Randolph, James S. Hardwick, John F. Reilly, Cong Chen, Justin L. Ricker, J. Paul Secrist, Victoria M. Richon, Stanley R. Frankel, Hagop M. Kantarjian
Journal: Blood
Blood (2008) 111 (3): 1060–1066.
https://doi.org/10.1182/blood-2007-06-098061
Published: 2008
Includes: Supplemental data
Journal Articles

Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Provides Prolonged Safety and Clinical Benefit to Patients with Advanced Cutaneous T-Cell Lymphoma (CTCL).

Madeleine Duvic, Elise A. Olsen, Debra Breneman, Theresa R. Pacheco, Sareeta Parker, Eric C. Vonderheid, Justin L. Ricker, Syed Rizvi, Cong Chen, Kathleen Boileau, Paulette Cooley, Larisa J. Geskin
Journal: Blood
Blood (2007) 110 (11): 2582.
https://doi.org/10.1182/blood.V110.11.2582.2582
Published: 2007
Journal Articles

Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Combination with Bortezomib in Patients with Advanced Multiple Myeloma.

Donna M. Weber, Sundar Jagannath, Amitabha Mazumder, Ronald Sobecks, Gary J. Schiller, Maria Gavino, Chantelle Sumbler, Carrie McFadden, Cong Chen, Justin L. Ricker, Syed Rizvi, Carol Oerth, Patricia Brownell, Mohamad A. Hussein
Journal: Blood
Blood (2007) 110 (11): 1172.
https://doi.org/10.1182/blood.V110.11.1172.1172
Published: 2007
Journal Articles

Final Results of a Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Advanced Multiple Myeloma.

Paul G. Richardson, Constantine S. Mitsiades, Kathleen Colson, Eileen Reilly, Laura McBride, Judy Chiao, Linda Sun, Justin L. Ricker, Syed Rizvi, Carol Oerth, Barbara Atkins, Ivy Fearen, Kenneth C. Anderson, David S. Siegel
Journal: Blood
Blood (2007) 110 (11): 1179.
https://doi.org/10.1182/blood.V110.11.1179.1179
Published: 2007
Journal Articles

Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Provides Prolonged Clinical Benefit to Advanced Cutaneous T-Cell Lymphoma Patients: Updated Results of the Phase IIb Multicenter Clinical Trial.

Madeleine Duvic, MD, Youn H. Kim, MD, Timothy M. Kuzel, MD, Theresa R. Pacheco, MD, Francine M. Foss, MD, Sareeta Parker, MD, Stanley R. Frankel, MD, Cong Chen, PhD, Justin L. Ricker, MD, PhD, Jean Marie Arduino, PhD, Sophia Randolph, MD, PhD, Victoria M. Richon, PhD, Elise A. Olsen, MD
Journal: Blood
Blood (2006) 108 (11): 399.
https://doi.org/10.1182/blood.V108.11.399.399
Published: 2006
Journal Articles

Identification of Informative Gene Expression Signatures Indicative of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Exposure and Clinical Efficacy in Patients with Advanced Cutaneous T-Cell Lymphoma.

Andrey Loboda, PhD, Valeria Fantin, PhD, Sophia Randolph, MD, PhD, Justin L. Ricker, MD, PhD, James S. Hardwick, PhD, Victoria M. Richon, PhD, Stanley R. Frankel, MD
Journal: Blood
Blood (2006) 108 (11): 4686.
https://doi.org/10.1182/blood.V108.11.4686.4686
Published: 2006
Journal Articles

Clinical Responses to Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Are Associated with Specific Gene Expression Signatures in Patients with Advanced Leukemias: Results of a Phase I Trial.

Andrey Loboda, PhD, Valeria R. Fantin, PhD, Carlos E. Bueso-Ramos, MD, PhD, Sophia Randolph, MD, PhD, James S. Hardwick, PhD, Justin L. Ricker, MD, PhD, Victoria M. Richon, PhD, Jean-Pierre Issa, MD, Hagop M. Kantarjian, MD, Stanley R. Frankel, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2006) 108 (11): 2320.
https://doi.org/10.1182/blood.V108.11.2320.2320
Published: 2006
Journal Articles

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Clinical Trials & Observations
Madeleine Duvic, Rakshandra Talpur, Xiao Ni, Chunlei Zhang, Parul Hazarika, Cecilia Kelly, Judy H. Chiao, John F. Reilly, Justin L. Ricker, Victoria M. Richon, Stanley R. Frankel
Journal: Blood
Blood (2006) 109 (1): 31–39.
https://doi.org/10.1182/blood-2006-06-025999
Published: 2006